CHAMGAP
VERIFIEDPassed the Codex final verification and publication gate. Evidence-verification cutoff: 2026-09-07. AI was used for research and drafting; the existence of all 1 cited sources was verified at the original page, followed by blind grading, adversarial audit, and build validation. Methodology v0.8.
Verdict No. 2987 · Search date 2026-09-07 · Methodology v0.8

Oral lactoferrin 350 mg/day added from the day after small-incision cataract surgery,
does it really help with Improved tear-breakup time, Schirmer testing, and dry-eye symptoms at 60 days after surgery?

30-Second Summary
C
Evidence Grade C · 54 · Safety acceptable
This was a small open-label postoperative cataract trial and does not establish efficacy for chronic dry-eye disease in general
No analyzed participant reported diarrhea, appetite loss, rash, or constipation. The trial cannot establish long-term safety in people with milk-protein allergy, other illnesses, or interacting medicines.
What the
research shows
Grade C. In an open-label trial randomizing 64 cataract patients without pre-existing dry eye and analyzing 58 completers, 60-day tear-breakup time was 13.9 seconds with lactoferrin versus 7.86 seconds with control, and Schirmer testing was 30.9 versus 15.86 mm. The differences were large, but there was no placebo or masking, only completers were analyzed, and the population had postoperative rather than general chronic dry eye.
What the
ads claim
Saying that lactoferrin treats all dry eye erases the postoperative population and the open-label no-placebo design.
*

Useful facts when choosing a product

  • The tested oral dose was 350 mg/day.
  • Treatment began after small-incision cataract surgery and lasted 60 days.
  • No multivitamin or omega-3 combination was tested.
Gap Measurement · Verdict 2987 · C 54
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Sixty-four small-incision cataract patients were simply randomized 32/32 to routine postoperative care with or without lactoferrin 350 mg/day. Six did not complete follow-up, leaving 28 and 30 analyzed. At day 60, tBUT was 7.86 versus 13.9 seconds, Schirmer was 15.86 versus 30.9 mm, and at least mild OSDI symptoms occurred in 42.8% versus 26.6%.

02

Why this is classified as C (54)

Large objective differences provide a human efficacy signal, but completer analysis, n=64, 60 days, open-label no-placebo design, and a narrow postoperative population give C with 54 points.

Counterpoint. No participant reported diarrhea, loss of appetite, rash, or constipation during the study.

Rejudgment record. Codex PMC full-text, bibliographic, and scoring cross-check — Accepted large tBUT and Schirmer effect sizes and independent randomization while accounting for completer analysis, n=64, 60 days, open-label no-placebo design, and postoperative population restriction

Scoring profile behind this grade
EndpointSSurrogate marker - laboratory or imaging measures
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improved tear-film tests 60 days after cataract surgeryCBoth tBUT and Schirmer differed substantially.
Treatment of chronic dry-eye disease in general?Patients with pre-existing dry eye were excluded.

Cross-check — AI research and Codex final gate

AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Devendra J·Singh S. 2015Single-center nonblinded simple-randomized parallel trial60No financial or competing interests reportedTear-breakup time, Schirmer test 1, and OSDIDay-60 tBUT 13.9 vs 7.86 seconds; Schirmer 30.9 vs 15.86 mm; at least mild OSDI symptoms 26.6% vs 42.8%Large objective signal in an open-label completer analysis
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-09-07).

Devendra J, Singh S. Effect of Oral Lactoferrin on Cataract Surgery Induced Dry Eye: A Randomised Controlled Trial. J Clin Diagn Res. 2015;9(10):NC06-NC09. PMID: 26557550. PMCID: PMC4625269. DOI: 10.7860/JCDR/2015/15797.6670.
checked
Research and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-07 · Corrections: none

Cite this verdict

Oral Lactoferrin for Dry Eye at 60 Days After Cataract Surgery Evidence Grade C card
[Chamgap] Oral Lactoferrin for Dry Eye at 60 Days After Cataract Surgery — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/eye/oral-lactoferrin-post-cataract-surgery-dry-eye/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.